1. Generics Bulletin
  2. >>Business
  3. >>Deals

Tabuk Makes MENA Deal For Prestige’s Trastuzumab

Pair Strike Agreement On Rights To Tuznue Biosimilar To Herceptin

 
• By Dave Wallace

Saudi firm Tabuk has struck a deal to sell Prestige BioPharma’s Tuznue trastuzumab biosimilar in the MENA region.

MENA Map At Night
The deal gives Tabuk rights to Prestige’s trastuzumab in the MENA region • Source: Shutterstock

Saudi generics and branded medicines supplier Tabuk Pharmaceuticals has struck a deal with Singapore-based Prestige BioPharma for the right to sell Prestige’s Tuznue (trastuzumab) biosimilar rival to Herceptin in the Middle East and North Africa region.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.